

<p>Substitute for FORM 1449A/B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p> <p>Sheet 1 of 1</p>		<p><i>Complete if Known</i></p> <table> <tr> <td>Application Number:</td> <td>10/572,582</td> </tr> <tr> <td>Filing Date:</td> <td>March 20, 2006</td> </tr> <tr> <td>First Named Inventor:</td> <td>PRABHAKAR, Bellur S</td> </tr> <tr> <td>Group Art Unit:</td> <td>1636</td> </tr> <tr> <td>Confirmation Number:</td> <td></td> </tr> <tr> <td>Examiner Name:</td> <td>Hibbert</td> </tr> <tr> <td>Attorney Docket Number:</td> <td>21726-103049</td> </tr> </table>		Application Number:	10/572,582	Filing Date:	March 20, 2006	First Named Inventor:	PRABHAKAR, Bellur S	Group Art Unit:	1636	Confirmation Number:		Examiner Name:	Hibbert	Attorney Docket Number:	21726-103049
Application Number:	10/572,582																
Filing Date:	March 20, 2006																
First Named Inventor:	PRABHAKAR, Bellur S																
Group Art Unit:	1636																
Confirmation Number:																	
Examiner Name:	Hibbert																
Attorney Docket Number:	21726-103049																

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No ^{**}
/C.H./	AA	Al-Zoubi et al., "Contrasting Effects of IG20 and its Splice Isoforms, MADD and DENN-SV, on Tumor Necrosis Factor α -induced Apoptosis and Activation of Caspase-8 and -3," <i>Jrnl. of Biological Chem.</i> , 276:50 47202-47211 (2001)		
/C.H./	AB	Efimova et al., "Differential Effects of IG20 and Its Splice Isoform, DENN-SV, on Cell Proliferation and Apoptosis," <i>FASEB Jrnl.</i> , 16:5 A1083 (2002)		
/C.H./	AC	Efimova et al., "IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs," <i>Oncogene</i> , 23:5 1076-1087 (2004)		
/C.H./	AD	Hilger et al., "The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer," <i>Onkologie</i> , 25:6 511-518 (2002)		
/C.H./	AE	Schievella et al., "MADD, a Novel Death Domain Protein That Interacts with the Type 1 Tumor Necrosis Factor Receptor and Activates Mitogen-Activated Protein Kinase," <i>Jrnl. of Biological Chem.</i> , 272:18 12069-12075 (1997)		
/C.H./	AF	Zhang et al., "A splicing variant of a death domain protein that is regulated by a mitogen-activated kinase is a substrate for c-Jun N-terminal kinase in the human central nervous system," <i>Proc. Natl. Acad. Sci. USA</i> , 95: 2586-2591 (1998)		

CHDS01 AOM 407271v1

EXAMINER	/Catherine Hibbert/	DATE CONSIDERED	09/15/2009
----------	---------------------	-----------------	------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).